{"filings":[{"id":759241,"accession_number":"0001193125-26-249692","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2026-06-01T11:00:19+00:00","items":["3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.","Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.","Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.","Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.","Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90741,"accession_number":"0001193125-26-201408","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve reverse split range, authorized share reduction, equity plan amendments via written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.","Approved restated plan extending ISO grant period, further raising ISO limit, extending evergreen provision.","Approved reverse stock split at ratio 1:2 to 1:20, with board discretion for up to one year.","Approved decrease in authorized common shares from 500M to 100M, effective at board discretion within one year.","Votes cast by 4,324,964 shares (57.1% of outstanding) on April 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133272,"accession_number":"0001104659-25-076933","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Lindsay Androski resigns from Eloxx board effective August 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lindsay Androski notified the Board of her resignation, effective immediately on August 6, 2025.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","No replacement director has been announced; board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186029,"accession_number":"0001104659-24-109521","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.","Options granted under 2018 Equity Incentive Plan; exercisable in full as of Oct 16, 2024 regardless of vesting.","New exercise price set to $0.0001, the closing OTC price on the repricing date.","Option repricing approved by Board on Oct 16, 2024; amendment approved by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202608,"accession_number":"0001104659-24-080251","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.","Conversion options: Tranche 1A/1B debt can convert into equity if Qualified Financing ≥$7M occurs before April 2025.","Royalty Agreement: 33% of first three Almirall milestones and 25% of subsequent milestones, capped at $53M, plus 0.75% of ELX-02 and 0.50% of ZKN-013 revenue.","Amended Securities Purchase Agreement grants anti-dilution rights to SD MF for 15 months.","Reporting covenant for FY2023 audited financials extended to November 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238667,"accession_number":"0001104659-24-041148","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eloxx reprices CEO Sumit Aggarwal's options to $0.90 from $37.47 per share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Option repricing approved by Board on March 25, 2024 for CEO Sumit Aggarwal.","Exercise price reduced to $0.90 per share (closing price on March 25, 2024).","Affects 196,880 shares previously exercisable at weighted average $37.47.","All outstanding eligible options under 2018 Equity Incentive Plan included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238666,"accession_number":"0001104659-24-034529","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.","Tiered royalties on any future global sales of ZKN-013.","ZKN-013 is a Phase I ready oral therapy for nonsense mutations causing rare dermatologic diseases.","Almirall obtains worldwide rights to develop and commercialize ZKN-013."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238665,"accession_number":"0001104659-24-002631","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Eloxx Pharmaceuticals restructures debt; issues stock and warrants for $2M loan assignment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Fifth Amendment to Hercules Loan Agreement; $2M Tranche 1B Advance assigned to SD MF 4 LLC.","Issued 157,138 shares of common stock, pre-funded warrant for 471,508 shares, and warrant for 150,000 shares to assignee in exchange for debt assumption.","No cash proceeds from equity issuance; loan financial covenant for minimum cash balance removed for assigned tranche.","Interest may be paid in-kind on Tranche 1B; principal amortization deferrable at assignee's option.","Company must file resale registration statement within 15 days; exercise prices: pre-funded $0.001, additional $1.18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256163,"accession_number":"0001104659-23-130052","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eloxx Pharma Chairman Tomer Kariv resigns from board effective Dec 27","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tomer Kariv resigned as Director, Chairman of the Board, and committee member effective December 27, 2023.","Resignation is not due to any disagreement with the Company's operations, policies, or practices.","Company's common stock currently quoted on OTC Pink following Nasdaq delisting appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256162,"accession_number":"0001104659-23-126400","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Eloxx amends Hercules loan, repays $1M; cash covenant lowered to $1.05M through Jan 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Minimum qualified cash reduced to $1.05M from Dec 15, 2023 to Jan 25, 2024.","Company repaid $1.0M of principal; remaining Term Loan principal is $3.1M.","After Jan 25, minimum cash reverts to $1.05M plus accounts payable unpaid over 180 days.","Amendment provides temporary liquidity relief amid cash constraints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256161,"accession_number":"0001104659-23-117308","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx reports Q3 net loss of $3.6M; positive Phase 2 data for ELX-02; Nasdaq delisting appeal pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.","Cash of $4.8M as of Sep 30; raised $3.8M in Q3; cash expected to fund operations only through end of Q4 2023.","Phase 2 open-label trial of ELX-02 in Alport Syndrome showed improved kidney morphology, collagen expression, and average 60% increase in filtration slit density.","Strategic partnership progress for ZKN-013; FDA clearance received for single ascending dose trial.","Common stock suspended on Nasdaq on Oct 16 and now trades on OTC Pink; appeal of delisting decision pending."],"consensus_eps_estimate":-2.0094,"consensus_eps_actual":-5.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256160,"accession_number":"0001104659-23-109423","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eloxx receives Nasdaq delisting notice; trading suspended Oct 16, shares to OTC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Eloxx on Oct 12, 2023 that it failed to regain compliance with $35M MVLS rule.","Trading of common stock (ELOX) suspended on Nasdaq effective Oct 16, 2023; will trade OTC under same symbol.","Company intends to request review by Nasdaq Listing Council, which stays delisting filing but not suspension.","Previously granted extensions expired Oct 9, 2023; stock has been below compliance threshold for over a year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273565,"accession_number":"0001104659-23-102293","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Eloxx Pharmaceuticals raises ~$2M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 305,590 shares + 75,000 pre-funded warrants at ~$5.255/unit, and 380,590 private warrants at $5.13 exercise.","Gross proceeds approximately $2.0M; H.C. Wainwright placement agent with 7.5% fee and 22,835 warrant shares.","Private and placement warrants issued unregistered under Section 4(a)(2) exemption.","Pre-funded warrant exercise price $0.001; private warrant term 5.5 years; both have beneficial ownership caps.","Proceeds intended for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273564,"accession_number":"0001104659-23-101394","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eloxx reports positive kidney biopsy results from Phase 2 ELX-02 trial in Alport syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three patients showed improvement in foot process effacement on TEM kidney biopsies after 8 weeks of ELX-02 treatment.","Patient 4401-02 achieved remission based on Urine-Protein Creatine Ratio (UPCR).","Patient 4402-01 showed wider intact foot process areas, though pre/post comparison was limited.","Company to seek FDA alignment on pivotal trial design and Breakthrough Therapy Designation for ELX-02."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273563,"accession_number":"0001104659-23-101272","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eloxx Pharma R&D head Dr. Vijay Modur resigns effective Sept 30, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Vijay Modur, Head of R&D, notified resignation effective September 30, 2023.","No successor or interim appointment was disclosed in the filing.","Resignation date of notification is September 15, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273562,"accession_number":"0001104659-23-098843","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.","Phase 2 open-label trial: Patient 4401-02 achieved remission with UPCR improving from 1,646 to 850 mg/g during treatment.","Two other patients (4401-01, 4402-01) did not achieve remission; UPCR increased post-treatment.","Data show on-treatment remission in one patient, confirming drug activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273561,"accession_number":"0001104659-23-096572","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eloxx Pharma Board approves retention program with performance-based equity grants to CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Sumit Aggarwal granted 75,000 performance RSUs and 25,000 performance stock options (exercise price $4.63).","Awards vest upon earliest of: $35M market cap, $25M capital raise, or change in control.","Future grants of 60,000 RSUs to CEO and 20,000 RSUs to Head of R&D Vijay Modur, subject to share availability.","Additional 50,000 stock option for CEO under same condition, with exercise price not greater than $4.63."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273560,"accession_number":"0001104659-23-093964","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eloxx posts updated corporate presentation; no new specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted on investors section of company website on August 21, 2023.","No financial data, pipeline updates, or strategic changes included in the filing.","Presentation title: 'RARE Thinking for RARE Solutions, Small Molecule Gene Therapy'.","No forward-looking guidance or material changes from prior disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273559,"accession_number":"0001104659-23-091130","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Pharma Q2 net loss $4.3M; cash only into Q4 2023; ELX-02 positive biopsy data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.3M ($1.96 EPS) vs $10.6M ($4.90 EPS) in prior-year quarter.","Cash $4.3M at June 30; raised $1.7M gross via ATM program post-quarter.","All 3 patients on ELX-02 showed improved podocyte foot process effacement in kidney biopsies; company plans pivotal Alport trial pending funding.","FDA cleared IND for ZKN-013 SAD study in RDEB; first dosing expected by end 2023.","Nasdaq extended compliance deadline for $35M market value listing rule to October 9, 2023."],"consensus_eps_estimate":-1.5708,"consensus_eps_actual":-4.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273558,"accession_number":"0001104659-23-087248","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eloxx receives Nasdaq extension to Oct 9, 2023 to meet $35M market value rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel extended compliance deadline for Listing Rule 5550(b)(2) from July 30 to October 9, 2023.","Company must maintain at least $35 million market value of listed securities to avoid delisting.","Extension follows a May 18, 2023 hearing and a July 27, 2023 request by Eloxx.","Failure to regain compliance by October 9 could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273557,"accession_number":"0001104659-23-080576","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.","Two other patients (4401-01, 4402-01) had no meaningful change in proteinuria.","All three patients had COL4A4 nonsense mutations and background RAAS blockade.","Patient 4401-02's remission rebounded 1 month after treatment withdrawal.","Results from KOL Day on June 27, 2023 disclosed via 8-K filed July 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290550,"accession_number":"0001104659-23-073875","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eloxx holders elect all 5 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Kariv (557,994 for), Aggarwal (511,136), Androski (559,991), Rubin (509,103), Walts (559,951).","Ratification of Baker Tilly as auditor passed with 1,181,736 for, 23,057 against, 48,182 abstain.","Advisory say-on-pay vote approved: 550,254 for, 12,373 against, 42,508 abstain; 647,840 broker non-votes.","Approximately 57.83% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290549,"accession_number":"0001104659-23-071430","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.","Overall ppFEV1 change was -0.31% at Day 35; disease progression pre-treatment averaged -4.26%/yr.","Safety follow-up at 28 days showed -2.69% ppFEV1 decline; no treatment-related serious adverse events.","Results bolster decision to advance ELX-02 into pivotal Alport syndrome trial.","Interim topline from 11 patients reported Sep 2022; final analysis confirms activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290548,"accession_number":"0001104659-23-068637","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.","Extension is conditioned on achievement of certain milestones included in a compliance plan.","Company plans to advance ELX-02 into pivotal study in Alport Syndrome patients with nonsense mutations.","Plans depend on completing third patient dosing in Phase 2 trial, FDA discussions, and obtaining necessary capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290547,"accession_number":"0001104659-23-063884","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.","Second patient showed no significant UPCR change; both had same Col4A4 mutation but different RAAS inhibitor levels.","ELX-02 generally well tolerated; no discontinuations; kidney biopsies showed no nephrotoxicity.","Entered ATM agreement with Oppenheimer for up to $50M common stock sales, currently limited to $6.5M due to S-3 limits.","Prior SVB Leerink ATM agreement terminated; no shares were sold under that agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290546,"accession_number":"0001104659-23-060978","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.","Cash and equivalents $4.9M at March 31; amended Hercules loan reduced minimum cash to $2.25M, interest-only until Sep 1, 2023.","Current cash expected to fund operations into Q3 2023, assuming Phase 3 activities start in Q3.","Topline data for ELX-02 in Alport syndrome (including biopsy) expected H1 2023; meaningful protein reduction seen in one patient.","FDA cleared ZKN-013 SAD trial for RDEB; preclinical showed up to 18-fold increase in full-length COL VII protein."],"consensus_eps_estimate":-2.601,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290545,"accession_number":"0001104659-23-045573","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.","Company failed to regain compliance during the 180-day grace period that ended April 10, 2023.","Trading will be suspended on April 20, 2023, unless company requests a hearing by April 18, 2023.","Company intends to appeal; a hearing request will stay the suspension pending Panel decision.","There is no assurance the appeal will succeed or that continued listing will be granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290544,"accession_number":"0001104659-23-040585","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.","Unrestricted cash $19.2M at Dec 31, 2022; amended Hercules loan repaid $7.5M; cash runway into Q3 2023.","Three patients dosed in Phase 2 ELX-02 for Alport; initial proteinuria reduction observed; topline data H1 2023.","IND filed for ZKN-013 for RDEB; preclinical read-through up to 18-fold increase in COL VII protein."],"consensus_eps_estimate":-2.601,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311442,"accession_number":"0000950170-23-007032","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Eloxx amends Hercules loan: no prepayment penalty, cash covenant cut to $2.25M, $7.5M repaid","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepayment premium eliminated (was 1-3%); company may prepay anytime without fee.","Interest-only period extended to Sep 1, 2023 (from Apr 1, 2023); further extension conditional on $35M equity raise.","Minimum cash covenant reduced from $6.3M-$10M to $2.25M; drops to $0 if $20M raised by May 31, 2023.","Company repaid $7.5M of principal as condition, reducing outstanding Term Loan to $5.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330024,"accession_number":"0001104659-22-123704","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Eloxx Pharmaceuticals effects 1-for-40 reverse stock split to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-40 approved by shareholders on Nov 30, 2022; board set ratio same day.","Effective at 5:00 PM ET on Dec 1, 2022; split-adjusted trading begins Dec 2 under symbol ELOX.","Goal is to raise per-share price above Nasdaq's minimum $1 bid requirement and maintain listing.","Fractional shares will be cashed out at closing price on Nov 30; no fractional shares issued.","Proportionate adjustments made to outstanding equity awards, warrants, and equity plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330023,"accession_number":"0001104659-22-118535","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.","Cash $24.6M as of Sep 30, 2022; expects funding into Q4 2023 subject to covenant compliance.","Phase 2 Alport trial (NCT05448755) dosed first patient; topline results expected H1 2023.","Phase 2 CF combination (ELX-02 + ivacaftor) did not meet efficacy endpoints; path forward to be determined with CF Foundation.","ZKN-013 IND for RDEB on track for end of 2022 / early 2023; preclinical data presented for TURBO-ZM platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330022,"accession_number":"0001104659-22-108877","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eloxx warned by Nasdaq: MVLS below $35M, faces potential delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Oct 11, 2022; MVLS below $35M minimum for 30 consecutive business days.","No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under symbol ELOX.","180-day compliance period until April 10, 2023 to regain compliance by closing MVLS at $35M+ for 10 consecutive days.","If compliance not regained, Nasdaq will provide delisting notification; Company may appeal to hearings panel.","Company intends to monitor MVLS and evaluate options but cannot assure regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347588,"accession_number":"0001104659-22-100245","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.","ELX-02 was well tolerated; no treatment-related serious adverse events reported.","Evidence of activity seen in patients with higher baseline sweat chloride (p=0.00013 at Day 35).","Steady-state lung drug levels averaged 2 µM, only 20% of lowest preclinical active concentration.","Company plans to start proof-of-concept trial for ELX-02 in Alport syndrome later in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347587,"accession_number":"0001104659-22-091222","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.","Cash and equivalents $30.0M as of June 30, 2022; sufficient to fund operations into Q4 2023; in compliance with debt covenants.","CF Phase 2 expansion arms top-line results expected by end of Q3 2022; inhaled delivery IND on track for Q4 2022.","Alport syndrome proof-of-concept trial to start H2 2022 in up to 8 patients; topline results expected H1 2023.","ZKN-013 repeat study confirms potential in FAP model; IND for FAP expected H2 2023; RDEB IND on track for Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347586,"accession_number":"0001104659-22-080012","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Eloxx Pharmaceuticals dismisses Deloitte, appoints Baker Tilly as auditor; no disagreements reported","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor; Baker Tilly US, LLP engaged for FY 2022, effective July 13, 2022.","No disagreements or reportable events between Eloxx and Deloitte during 2020, 2021, or through July 13, 2022.","Deloitte's audit reports for FY 2020 and 2021 included a going concern doubt about the company's ability to continue.","Deloitte confirmed agreement with the disclosures in a letter filed as Exhibit 16.1; no prior consultations with Baker Tilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347585,"accession_number":"0001104659-22-077083","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Eloxx Pharmaceuticals appoints Lindsay Androski to board; five directors resign, board shrinks from nine to five","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Five directors (Gadi Veinrib, Ran Nussbaum, Zafrira Avnur, Rajesh Parekh, Jasbir Seehra) resign effective July 1, 2022.","Board size reduced from nine to five directors; Alan Walts and Tomer Kariv appointed as committee chairs.","Lindsay Androski appointed to fill vacancy, joining Audit and Compensation Committees.","Androski is President/CEO of Roivant Social Ventures and was part of founding team at Roivant Sciences.","Company states resignations not due to any disagreement; aims for a 'nimble and focused' board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364077,"accession_number":"0001104659-22-071891","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eloxx shareholders elect all nine director nominees, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["50,160,111 shares present (57.88% of outstanding) at June 15, 2022 annual meeting.","All nine director nominees elected; votes for ranged from 21,179,908 to 25,579,083.","Ratification of Deloitte as auditor: 49,488,639 for, 598,786 against.","Advisory vote on executive compensation approved: 24,778,473 for, 1,082,703 against.","Broker non-votes were 24,280,981 on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364076,"accession_number":"0001104659-22-058351","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Q1 net loss $11.6M; CF award up to $15.9M; cash into Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.6M ($0.13/sh) vs $8.7M ($0.22/sh) in Q1 2021; R&D $7.9M, G&A $3.1M.","CF Foundation award up to $15.9M for ELX-02; Phase 2 CF topline results expected end H1 2022.","Expanded ELX-02 development to Alport syndrome; Phase 2 proof-of-concept trial for nonsense mutations starts H2 2022.","Cash $39.8M sufficient into Q2 2023; ZKN-013 IND for RDEB planned H2 2022."],"consensus_eps_estimate":-28.611,"consensus_eps_actual":-5.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364075,"accession_number":"0001104659-22-041986","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.","CF Foundation therapeutic award up to $15.9M for ELX-02 CF program; $7.0M upfront.","Phase 2 CF expansion (ELX-02+ivacaftor) topline results expected by end of H1 2022.","New Alport syndrome program for ELX-02; proof-of-concept trial in up to 8 patients expected H2 2022.","ZKN-013 FAP mouse model: 50% reduction in polyp burden, 40% in polyp count; 50% survival benefit."],"consensus_eps_estimate":-28.611,"consensus_eps_actual":-5.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383805,"accession_number":"0001104659-22-001026","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eloxx receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until July 5, 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of common stock below $1.00 for 30 consecutive business days as of Jan 3, 2022.","Company has until July 5, 2022 to regain compliance; may qualify for an additional 180-day grace period.","Options to cure include a reverse stock split; no assurance of regaining compliance.","Stock continues trading on Nasdaq Global Market under symbol ELOX during the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401643,"accession_number":"0001104659-21-140321","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.","ELX-02 well tolerated; no treatment-related serious adverse events; most common mild injection site reactions.","Planning for Phase 3 clinical development initiated; 1.5 mg/kg/day dose selected for further study.","First patient dosed in Phase 2 combination arm with ivacaftor; topline data expected by H1 2022.","Evaluation of inhaled delivery of ELX-02 started; IND submission planned for H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401642,"accession_number":"0001104659-21-136028","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.","Cash $52.4M as of Sep 30, 2021; expected to fund operations into Q1 2023.","Entered debt facility with Hercules Capital for up to $30M, initial draw $12.5M.","Appointed Dr. Ali Hariri as Chief Medical Officer.","FDA Fast Track designation for ELX-02; Phase 2 monotherapy data expected Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401641,"accession_number":"0001104659-21-122815","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-10-05T23:59:59+00:00","items":["1.01","2.01","2.03"],"status":"ready","headline":"Eloxx enters $30M loan agreement with Hercules; repays $6.7M prior loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loans up to $30M: Tranche 1 $12.5M funded Sep 30, 2021; Tranche 2 $7.5M subject to clinical milestones (available until Aug 15, 2022); Tranche 3 $10M subject to lender discretion.","Interest at greater of 9.50% or prime+6.25%; principal amortization begins April 2023, matures April 2025.","Used $7.7M to prepay and terminate prior Silicon Valley Bank loan ($6.67M outstanding, plus prepayment premium and final charge).","Loan secured by substantially all assets of Eloxx, Zikani Therapeutics (wholly owned), and Israeli subsidiary, excluding IP.","Customary covenants limit additional debt, dividends, asset sales; prepayment premium of 3%–1% depending on timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420588,"accession_number":"0001104659-21-121017","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-09-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Eloxx enters $50M at-the-market equity distribution agreement with SVB Leerink","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M in common stock may be sold through SVB Leerink as sales agent under ATM program.","SVB Leerink receives 3% commission on gross sales proceeds; company provides customary indemnification.","Shares sold pursuant to existing S-3 shelf registration and prospectus supplement dated Sept 30, 2021.","Company is not obligated to sell any shares; agreement can be terminated by either party at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420587,"accession_number":"0001104659-21-115077","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Eloxx Pharmaceuticals presents at H.C. Wainwright 23rd Annual Global Investment Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation scheduled for September 13–15, 2021; materials available on company website.","No financial results, guidance, or material disclosures included in the filing.","Routine investor conference presentation with no specific new information provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420586,"accession_number":"0001104659-21-108145","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eloxx Pharmaceuticals appoints Daniel Geffken as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Geffken, Interim CFO since April 1, 2021, added role of Principal Accounting Officer on August 17, 2021.","Geffken provides services through Danforth Advisors, LLC.","No departure or change in CFO role; Geffken remains Principal Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420585,"accession_number":"0001104659-21-106641","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.","Cash and equivalents $56.7M at June 30, 2021, expected to fund operations into Q1 2023.","ELX-02 Phase 2 CF monotherapy data on track for Q4 2021; combination arm with ivacaftor to start by end of 2021.","ZKN-013 nominated as lead candidate for RDEB/JEB; IND-enabling GLP studies expected by end of 2021.","Received up to $2.6M award from Cystic Fibrosis Foundation for oral ribosome modulating agents."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420584,"accession_number":"0001104659-21-093086","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eloxx Pharmaceuticals loses Principal Accounting Officer Gary Rakers effective July 30, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Rakers resigns as Executive Director, Finance & Accounting, Corporate Controller and Treasurer (Principal Accounting Officer).","Resignation effective July 30, 2021, to pursue another business opportunity.","Rakers had been with the company since January 2020.","Company has not yet named a successor; intends to appoint one as soon as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420583,"accession_number":"0001104659-21-089497","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Eloxx updates Phase 2 ELX-02 progress; COO Neil Belloff to depart by Aug 25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neil Belloff, COO and General Counsel, will transition and depart on or before August 25, 2021; will receive base salary and benefits through departure.","Phase 2 study of ELX-02 for cystic fibrosis: sufficient enrollment to assess biological activity; data from first four arms expected Q4 2021.","Fifth treatment arm added to evaluate ELX-02 in combination with Kalydeco (ivacaftor).","No drug-related serious adverse events reported; dose escalation proceeded to top dose level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}